Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

Shah, M. A.,Renfro, L. A.,Allegra, C. J.,André, T.,de Gramont, A.,Schmoll, H. J.,Ha

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients:

NCCTG N0147 (Alliance). Lee, A. M.,Shi, Q.,Alberts, S. R.,Sargent, D. J.,Sinicrope, F. A.,Berenberg, J. L.,Grothey,

Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy

Trial NCCTG N0147 (Alliance). Sinicrope, F. A.,Mahoney, M. R.,Yoon, H. H.,Smyrk, T. C.,Thibodeau, S. N.,Goldberg, R. M.,Nelson, G. D.,Sargent, D.

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

Sinicrope, F. A.,Shi, Q.,Smyrk, T. C.,Thibodeau, S. N.,Dienstmann, R.,Guinney, J.,Bot, B. M.,Tejpar, S.,Delorenzi, M.,Goldberg, R. M.,Mahoney, M.,Sargent, D. J

ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer.

Renfro, L. A.,Grothey, A.,Xue, Y.,Saltz, L. B.,André, T.,Twelves, C.,Labianca, R.,Allegra, C. J.,Alberts, S. R.,Loprinzi, C. L.,Yothers, G.,Sargent, D. J.;